HCWB
HCW Biologics Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.23
−0.81%Year over year
Reported trailing growth
- Revenue
- +707.0%
- EBITDA
- +46.7%
- EBIT
- +49.9%
- EPS
- -31.4%
- Free cash flow
- +4.5%
- Operating cash flow
- +3.4%
Forward estimates
Based on analyst estimates
- Revenue
- -98.5%
- EBITDA
- +93.1%
- EPS
- +97.4%
Three-year CAGR
- Revenue
- -79.9%
- EBITDA
- +79.5%
- EBIT
- +61.8%
- Net income
- +73.5%
- EPS
- —
- Free cash flow
- +7.6%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026